GleamWall
中文EN

BCAX Bicara Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2023658 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-81.3%
TTM EPS YoY-164.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-54.2%
ROA-49.8%
ROIC (approx.)-67.1%
Asset turnover—

Leverage & solvency

Liabilities / assets11.1%
Debt / equity0.00x
Current ratio8.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense—$63.60M
SG&A expense$30.51M$18.77M
Operating income-$155.60M-$82.39M
Pretax income-$137.73M-$67.81M
Income tax$217,000$187,000
Net income-$137.95M-$68.00M
EBITDA-$155.50M-$82.33M
EPS (basic)-2.52-4.05
EPS (diluted)-2.52-4.05
Weighted avg. shares (diluted)54.68B16.81B
Balance sheet
Cash & equivalents$96.69M$489.71M
Short-term investments$318.12M$0
Current assets$422.05M$502.53M
PP&E, net$330,000$155,000
Total assets$430.99M$510.00M
Current liabilities$28.95M$17.99M
Total liabilities$29.54M$18.12M
Shareholders' equity$401.45M$491.88M
Shares outstanding56.60M54.44M
Cash flow statement
Operating cash flow-$106.83M-$74.75M
Capital expenditure$280,000$71,000
Free cash flow-$107.11M-$74.82M
Investing cash flow-$318.45M-$9,000
Financing cash flow$32.26M$334.03M
Depreciation & amortization$105,000$56,000
Stock-based compensation$15.01M$7.40M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.